| Literature DB >> 29256159 |
Mallika Pathak1,2, Himanshu Ojha3,4, Anjani K Tiwari2, Deepti Sharma5, Manisha Saini1, Rita Kakkar2.
Abstract
Dihydrofolate reductase (Entities:
Keywords: 3D7 strain; Antimalarial; DHFR inhibitors; Molecular docking; s-Triazine
Year: 2017 PMID: 29256159 PMCID: PMC5735044 DOI: 10.1186/s13065-017-0362-5
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Structural features of the designed inhibitors and predicted pMIC values
| Designed inhibitor | R group | Predicted log1/ | Designed inhibitor | R group | Predicted p |
|---|---|---|---|---|---|
|
|
| − 4.47 |
|
| − 3.46 |
|
|
| − 3.84 |
|
| − 0.90 |
|
|
| − 3.19 |
|
| − 2.93 |
|
|
| − 3.41 |
|
| − 1.85 |
|
|
| − 2.62 |
|
| − 2.29 |
|
|
| − 2.78 |
|
| − 3.23 |
|
|
| 0.65 |
|
| 0.44 |
|
|
| 0.19 |
|
| − 2.2 |
|
|
| − 0.13 |
|
| − 3.88 |
|
|
| 0.58 |
|
| − 4.05 |
|
|
| − 2.76 |
|
| − 6.8 |
The ADME properties and Glide score of the selected six lead candidates
| Lead compounds | logPo/Wa | logSb | PCacoc | loghsad | logBB | logKp | % human oral absorptione | Glide score for inhibition of Pf-DHFR (Kcal/mol) |
|---|---|---|---|---|---|---|---|---|
|
| 2.421 | − 5.30 | 27.88 | 0.09 | − 3.01 | − 3.93 | 54.03 | − 6.23 |
|
| 3.841 | − 6.17 | 551.04 | 0.58 | − 0.72 | − 3.15 | 100.00 | − 5.41 |
|
| 4.614 | − 6.39 | 184.56 | 0.59 | − 2.30 | − 2.05 | 81.56 | − 5.25 |
|
| 3.333 | − 6.15 | 100.16 | 0.31 | − 2.42 | − 3.06 | 69.31 | − 4.74 |
|
| 2.778 | − 4.19 | 619.07 | 0.05 | − 0.97 | − 2.81 | 93.17 | − 4.64 |
|
| 2.409 | − 3.75 | 37.21 | 0.33 | − 0.36 | − 7.04 | 96.13 | − 4.25 |
|
| – | – | – | – | – | – | – | − |
alogPo/w (− 2.0 to 6.5)
blogS (− 6.5 to 0.5)
cPcaco < 25 is very poor and < 500 is great
dlogKhsa (− 1.5 to 1.5)
e% human oral absorption (< 25% is poor and > 80% is high)
Fig. 13-D docked for binding of compound no 18 in the active site of DHFR
Fig. 23-D docked for binding of compound no 7 in the active site of DHFR
Fig. 33-D docked for binding of compound no 13 in the active site of DHFR
Scheme 1Scheme for the synthesis of 1,3,5-triazine (s-triazine) derivatives (7, 13 and 18). Regents: (a) p-nitroaniline, K2CO3 in THF, (b) 1-chloro-4-ethylpiperazine, K2CO3, 18-Crown-6 in dry THF (refluxed for 2.5 h), (c) 1-chloro-4-ethylpiperazine, K2CO3, 18-Crown-6 in dry CH3CN (refluxed for 3 h), (d) 3-(chloroamino)phenol, K2CO3, 18-Crown-6 in dry CH3CN (refluxed for 3 h)
Synthesized trisubstituted triazine compounds
| Compound no. | HNu1 | HNu2 = HNu3 |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
|
MIC values of the synthesized 2,4,6-trisubstituted-1,3,5-triazine derivatives against 3D7 strain of P. falciparum
| Compound | Minimum inhibitory concentrationa |
|---|---|
|
| 4.466 |
|
| 7.94 |
|
| 2.75 |
|
| 255 |
aMinimum inhibitory concentration for the development of ring stage parasite into the schizont stage during 48 h incubation